Notice2026-00820
National Institute on Drug Abuse; Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 16, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 11 (Friday, January 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 11 (Friday, January 16, 2026)]
[Notices]
[Pages 2136-2137]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-00820]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual meeting and is open to the
public, as indicated below. Individuals who plan to view the virtual
meeting and need special assistance such as sign language
interpretation or other reasonable accommodations to view the meeting,
should notify Dr. Gillian Acca via email at <a href="/cdn-cgi/l/email-protection#1c7b757070757d72327d7f7f7d5c727574327b736a"><span class="__cf_email__" data-cfemail="5d3a343131343c33733c3e3e3c1d333435733a322b">[email protected]</span></a> ten
days in advance of the meeting. The open session will be videocast and
can be accessed from the NIH Videocasting and Podcasting website
(<a href="http://videocast.nih.gov/">http://videocast.nih.gov/</a>).
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C.,
[[Page 2137]]
as amended. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: February 3, 2026.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Presentations and other business of the Council.
Meeting Format: Virtual Meeting.
Place: National Institutes of Health, National Institute on Drug
Abuse, Three White Flint North, 11601 Landsdown Street, Bethesda, MD
20852.
Contact Person: Susan R.B. Weiss, Ph.D., Director Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852, 301-443-6480, <a href="/cdn-cgi/l/email-protection#f88b8f9d918b8bb896919c99d6969190d69f978e"><span class="__cf_email__" data-cfemail="473430222e343407292e232669292e2f69202831">[email protected]</span></a>.
Contact Person: Gillian Acca, Ph.D., Health Scientist
Administrator, Division of Extramural Research, Office of Extramural
Policy, National Institute on Drug Abuse, NIH, Three White Flint
North, RM 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-
827-5863, <a href="/cdn-cgi/l/email-protection#25424c49494c444b0b44464644654b4c4d0b424a53"><span class="__cf_email__" data-cfemail="abccc2c7c7c2cac585cac8c8caebc5c2c385ccc4dd">[email protected]</span></a>.
The meeting identified below has been scheduled in the event the
Council is unable to complete all agenda items identified for the
February 3, 2026, meeting. Information on the agenda items and/or
the necessity to hold the meeting listed below will be posted on the
Institute/Center homepage (link identified below).
Name of Committee: National Advisory Council on Drug Abuse.
Date: March 9, 2026.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications not completed
at the February meeting.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Presentations and other business of the Council not
completed at the February meeting.
Meeting Format: Virtual Meeting.
Place: National Institutes of Health, National Institute on Drug
Abuse, Three White Flint North, 11601 Landsdown Street, Bethesda, MD
20852.
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852, 301-443-6480, <a href="/cdn-cgi/l/email-protection#ed9e9a88849e9ead8384898cc3838485c38a829b"><span class="__cf_email__" data-cfemail="fb888c9e928888bb95929f9ad5959293d59c948d">[email protected]</span></a>.
Contact Person: Gillian Acca, Ph.D., Health Scientist
Administrator, Division of Extramural Research, Office of Extramural
Policy, National Institute on Drug Abuse, NIH, Three White Flint
North, RM 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-
827-5863, <a href="/cdn-cgi/l/email-protection#6007090c0c09010e4e01030301200e09084e070f16"><span class="__cf_email__" data-cfemail="b7d0dedbdbded6d999d6d4d4d6f7d9dedf99d0d8c1">[email protected]</span></a>.
Any interested person may file written comments with the
committee by forwarding the statement to Dr. Gillian Acca via email
at <a href="/cdn-cgi/l/email-protection#1f78767373767e71317e7c7c7e5f71767731787069"><span class="__cf_email__" data-cfemail="13747a7f7f7a727d3d72707072537d7a7b3d747c65">[email protected]</span></a>. The statement should include the name,
address, telephone number and when applicable, the business or
professional affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: <a href="http://www.drugabuse.gov/NACDA/NACDAHome.html">www.drugabuse.gov/NACDA/NACDAHome.html</a>, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Zieta M. Charles,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2026-00820 Filed 1-15-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 16, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.